Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 7, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: November 3, 2005
- Previous Holding: 18,326,595 ADRs
- New Holding: 18,405,230 ADRs
- Average Price: $51.34
Directors Dr. J.P. Garnier and Dr. T. Yamada are noted as potentially interested in the shares held in this discretionary fund, similar to other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of November 3, 2005 (18,405,230).
- Confirm the average transaction price of $51.34 for the movement in the fund.
- Note that Directors Dr. J.P. Garnier and Dr. T. Yamada have a potential interest in the fund's holdings.